Related Experiment Video
Updated: Aug 6, 2026
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric
Xin Liu1, Fangjia Tong2, Jiayi Zhang1
1Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Abstract:
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic malignancies, yet its efficacy in solid tumors and durability across broader application remain limited. A central challenge lies in how CAR signaling is initiated, amplified, and regulated over time. Unlike the native T cell receptor (TCR), CARs are synthetic, modular receptors whose signaling output is dictated by the composition and spatial organization of their extracellular, transmembrane, and intracellular domains. Emerging evidence suggests that CAR signaling requirements are not static: insufficient signaling at early time points can impair activation and tumor clearance, whereas excessive or prolonged signaling promotes exhaustion, toxicity, and loss of persistence. More recent CAR designs therefore emphasize fine-tuned signaling, embracing a "less-is-more" paradigm to balance potency with durability. In this review, we summarized recent advances in CAR signaling biology, focusing on temporal signaling thresholds, modular design principles, and emerging strategies to precisely control signal strength and quality. Finally, we discuss how high-throughput screening, computational modeling, and machine learning approaches may enable disease-specific, personalized CAR designs in the future.
Insights
Chimeric antigen receptor (CAR) T cell therapy needs optimized signaling for solid tumors. Fine-tuning CAR signaling balances potency and durability, improving persistence and reducing toxicity for better cancer treatment.
Area of Science:
- Immunology
- Biotechnology
- Cancer Research
Background:
- Chimeric antigen receptor (CAR) T cell therapy shows promise in hematologic cancers but faces limitations in solid tumors.
- CAR signaling initiation, amplification, and regulation are critical challenges impacting efficacy and durability.
- CARs are synthetic receptors with signaling output dependent on their modular components and organization.
Purpose of the Study:
- To review advances in CAR signaling biology.
- To focus on temporal signaling thresholds and modular design principles.
- To discuss strategies for precise control of CAR signal strength and quality.
Main Methods:
- Literature review of recent advances in CAR signaling.
- Analysis of CAR design principles and their impact on signaling.
- Discussion of emerging strategies for signal modulation.
Main Results:
- CAR signaling requirements are dynamic, with insufficient or excessive signaling leading to impaired efficacy or exhaustion.
- A "less-is-more" approach in CAR design aims to balance potency with durability.
- Fine-tuning signal strength and quality is crucial for improved CAR T cell function.
Conclusions:
- Optimizing CAR signaling is key to enhancing efficacy in solid tumors and improving treatment durability.
- Future CAR designs may leverage high-throughput screening, computational modeling, and machine learning for personalized approaches.
- Precise control over CAR signal dynamics holds the potential for next-generation immunotherapies.
